Abstract |
Mutations in the genes encoding isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) are key drivers of diverse cancers, including gliomas and hematological malignancies. IDH mutations cause neomorphic enzymatic activity that results in the production of the oncometabolite 2-hydroxyglutarate (2-HG). In addition to 2-HG's well-known effects on tumor cells themselves, it has become increasingly clear that 2-HG directly influences the tumor microenvironment (TME). In particular, the non-cell-autonomous impact of 2-HG on the immune system likely plays a major role in shaping disease development and response to therapy. It is therefore critical to understand how IDH mutations affect the metabolism, epigenetics, and functions of tumor-infiltrating immune cells. Such knowledge may point towards new therapeutic approaches to treat IDH-mutant cancers.
|
Authors | Julie Leca, Jerome Fortin, Tak W Mak |
Journal | Current opinion in biotechnology
(Curr Opin Biotechnol)
Vol. 68
Pg. 181-185
(04 2021)
ISSN: 1879-0429 [Electronic] England |
PMID | 33360716
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Copyright | Copyright © 2020 Elsevier Ltd. All rights reserved. |
Chemical References |
|
Topics |
- Cell Physiological Phenomena
- Epigenomics
- Glioma
- Humans
- Isocitrate Dehydrogenase
(genetics)
- Mutation
- Tumor Microenvironment
(genetics)
|